vs
Side-by-side financial comparison of Safehold Inc. (SAFE) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $97.9M, roughly 1.3× Safehold Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 6.5%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 2.5%).
SAFE Investment Company Limited is a Chinese sovereign wealth fund based in Hong Kong.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
SAFE vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $97.9M | $129.7M |
| Net Profit | $27.9M | — |
| Gross Margin | 98.6% | 98.0% |
| Operating Margin | 27.4% | -25.0% |
| Net Margin | 28.5% | — |
| Revenue YoY | 6.5% | 73.4% |
| Net Profit YoY | 7.1% | — |
| EPS (diluted) | $0.38 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $97.9M | $129.7M | ||
| Q3 25 | $96.2M | $164.9M | ||
| Q2 25 | $93.8M | $114.4M | ||
| Q1 25 | $97.7M | $81.7M | ||
| Q4 24 | $91.9M | $74.8M | ||
| Q3 24 | $90.7M | $62.9M | ||
| Q2 24 | $89.9M | $54.1M | ||
| Q1 24 | $93.2M | $41.4M |
| Q4 25 | $27.9M | — | ||
| Q3 25 | $29.3M | $25.7M | ||
| Q2 25 | $27.9M | $-12.8M | ||
| Q1 25 | $29.4M | $-41.2M | ||
| Q4 24 | $26.0M | — | ||
| Q3 24 | $19.3M | $-54.8M | ||
| Q2 24 | $29.7M | $-70.4M | ||
| Q1 24 | $30.7M | $-136.1M |
| Q4 25 | 98.6% | 98.0% | ||
| Q3 25 | 98.5% | 99.0% | ||
| Q2 25 | 99.1% | 98.7% | ||
| Q1 25 | 98.8% | 94.3% | ||
| Q4 24 | 98.8% | 96.6% | ||
| Q3 24 | 98.8% | 97.4% | ||
| Q2 24 | 98.8% | 96.2% | ||
| Q1 24 | 98.8% | 96.4% |
| Q4 25 | 27.4% | -25.0% | ||
| Q3 25 | 25.9% | 15.1% | ||
| Q2 25 | 25.5% | -11.1% | ||
| Q1 25 | 25.9% | -52.2% | ||
| Q4 24 | 24.6% | -81.2% | ||
| Q3 24 | 17.5% | -89.3% | ||
| Q2 24 | 26.7% | -125.1% | ||
| Q1 24 | 26.4% | -336.5% |
| Q4 25 | 28.5% | — | ||
| Q3 25 | 30.5% | 15.6% | ||
| Q2 25 | 29.8% | -11.1% | ||
| Q1 25 | 30.1% | -50.4% | ||
| Q4 24 | 28.3% | — | ||
| Q3 24 | 21.3% | -87.1% | ||
| Q2 24 | 33.0% | -130.1% | ||
| Q1 24 | 33.0% | -328.9% |
| Q4 25 | $0.38 | $0.04 | ||
| Q3 25 | $0.41 | $0.28 | ||
| Q2 25 | $0.39 | $-0.14 | ||
| Q1 25 | $0.41 | $-0.47 | ||
| Q4 24 | $0.36 | $-0.71 | ||
| Q3 24 | $0.27 | $-0.70 | ||
| Q2 24 | $0.42 | $-0.91 | ||
| Q1 24 | $0.43 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $21.7M | $93.0M |
| Total DebtLower is stronger | $4.6B | — |
| Stockholders' EquityBook value | $2.4B | $114.8M |
| Total Assets | $7.2B | $605.2M |
| Debt / EquityLower = less leverage | 1.90× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.7M | $93.0M | ||
| Q3 25 | $12.1M | $110.9M | ||
| Q2 25 | $13.9M | $75.2M | ||
| Q1 25 | $17.3M | $61.9M | ||
| Q4 24 | $8.3M | $58.5M | ||
| Q3 24 | $15.6M | $36.4M | ||
| Q2 24 | $13.4M | $32.3M | ||
| Q1 24 | $11.3M | $43.3M |
| Q4 25 | $4.6B | — | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.4B | — | ||
| Q1 25 | $4.3B | — | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.3B | — | ||
| Q2 24 | $4.2B | — | ||
| Q1 24 | $4.1B | — |
| Q4 25 | $2.4B | $114.8M | ||
| Q3 25 | $2.4B | $73.6M | ||
| Q2 25 | $2.4B | $32.7M | ||
| Q1 25 | $2.4B | $32.8M | ||
| Q4 24 | $2.3B | $59.1M | ||
| Q3 24 | $2.3B | $-30.5M | ||
| Q2 24 | $2.3B | $15.1M | ||
| Q1 24 | $2.3B | $74.1M |
| Q4 25 | $7.2B | $605.2M | ||
| Q3 25 | $7.1B | $538.6M | ||
| Q2 25 | $7.1B | $555.3M | ||
| Q1 25 | $6.9B | $548.8M | ||
| Q4 24 | $6.9B | $594.1M | ||
| Q3 24 | $6.8B | $504.4M | ||
| Q2 24 | $6.8B | $551.1M | ||
| Q1 24 | $6.7B | $663.5M |
| Q4 25 | 1.90× | — | ||
| Q3 25 | 1.89× | — | ||
| Q2 25 | 1.87× | — | ||
| Q1 25 | 1.85× | — | ||
| Q4 24 | 1.84× | — | ||
| Q3 24 | 1.88× | — | ||
| Q2 24 | 1.81× | — | ||
| Q1 24 | 1.81× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $47.8M | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $47.8M | $60.7M | ||
| Q3 25 | $-1.4M | $14.3M | ||
| Q2 25 | $28.0M | $5.0M | ||
| Q1 25 | $8.9M | $-42.2M | ||
| Q4 24 | $37.9M | $-35.7M | ||
| Q3 24 | $8.3M | $-42.5M | ||
| Q2 24 | $24.8M | $-40.2M | ||
| Q1 24 | $-3.1M | $-119.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $14.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-40.3M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -74.5% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | 1.72× | — | ||
| Q3 25 | -0.05× | 0.56× | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | 1.45× | — | ||
| Q3 24 | 0.43× | — | ||
| Q2 24 | 0.83× | — | ||
| Q1 24 | -0.10× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SAFE
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $60.3M | 62% |
| Other | $33.7M | 34% |
| Stabilized Properties | $3.8M | 4% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
